Tyrosine kinase inhibitors specifically block the activity of oncogenic tyrosine kinases. (A) The experimental design to evaluate the common target genes of oncogenic tyrosine kinases by specific inhibitors (imatinib and MLN518) is shown schematically. (B) Western blot analysis of murine 32Dcl3 cells transduced with various oncogenic tyrosine kinases using c-Abl, FLT3, or PDGFβR antibodies. Untransduced 32Dcl3 cells were used as a negative control. (C) Western blot analysis of transduced 32Dcl3 cells treated with either imatinib or MLN518 using a Phospho-Stat5 (Tyr694; top panel) or Stat5b antibody (bottom panel). 32D/BCR-ABL cells treated with MLN518 or 32D/FLT3-ITD cells treated with imatinib were used as a negative control.